Disease Landscape and Forecast Insights

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 735 currently available and novel biosimilar products, detailing…

Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…

Immunoglobulin A nephropathy (IgAN) is an autoimmune disease characterized by the accumulation of IgA in the glomeruli and impaired kidney function. RAAS inhibitors and SGLT-2 inhibitors are widely…

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

Pancreatic cancer remains difficult to treat owing to the lack of treatment options—primarily surgery, radiation, and chemotherapy. Pancreatic adenocarcinoma represents the vast majority of…

Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…

Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…